Androgen receptor signaling in prostate cancer development and progression
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The androgen receptor (AR) signaling axis plays a critical role in the development, function and homeostasis of the prostate. The classical action of AR is to regulate gene transcriptional processes via AR nuclear translocation, binding to androgen response elements on target genes and recruitment of, or crosstalk with, transcription factors. Prostate cancer initiation and progression is also uniquely dependent on AR. Androgen deprivation therapy remains the standard of care for treatment of advanced prostate cancer. Despite an initial favorable response, almost all patients invariably progress to a more aggressive, castrate-resistant phenotype. Considerable evidence now supports the concept that development of castrate-resistant prostate cancer (CRPC) is causally related to continued transactivation of AR. Understanding the critical events and complexities of AR signaling in the progression to CRPC is essential in developing successful future therapies. This review provides a synopsis of AR structure and signaling in prostate cancer progression, with a special focus on recent findings on the role of AR in CRPC. Clinical implications of these findings and potential directions for future research are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Phosphorylation and activation of androgen receptor by Aurora-A.
Shu, S.-K., Liu, Q., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121129 · Cited by 38
RetractedRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“[8-10] This evolution from a clinically localized hormone-naïve state to a castrate-resistant phenotype involves a complex interplay of a network of signaling molecules and is attributed to aberrant AR signaling.[10-13]”
BackgroundDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 15×
“A considerable body of evidence now exists that implicates extracellular peptide signals in the form of growth factors and cytokines in the maintenance of the transcriptional activity of AR in CRPC.”
BackgroundInfluentialA signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Steroid receptor coactivator-1 is a histone acetyltransferase
Spencer, T. E., Jenster, G., Burcin, M. M., Allis, C. D., Zhou, J., Mizzen, C. A., McKenna, N. J., Onate, S. A., Tsai, S. Y., Tsai, M.-J., et al. (1997) · Nature · doi:10.1038/38304 · Cited by 1,243
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,234
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025 · cited 1×
“[8-10] This evolution from a clinically localized hormone-naïve state to a castrate-resistant phenotype involves a complex interplay of a network of signaling molecules and is attributed to aberrant AR signaling.[10-13]”
BackgroundDeterminants of target gene specificity for steroid/thyroid hormone receptors
Umesono, K., & Evans, R. M. (1989) · Cell · doi:10.1016/0092-8674(89)90051-2 · Cited by 948
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Role of CBP/P300 in nuclear receptor signalling
Chakravarti, D., LaMorte, V. J., Nelson, M. C., Nakajima, T., Schulman, I. G., Juguilon, H., Montminy, M., & Evans, R. M. (1996) · Nature · doi:10.1038/383099a0 · Cited by 930
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja, M. J., Savinainen, K., Saramäki, O. R., Tammela, T. L. J., Vessella, R. L., & Visakorpi, T. (2001) · PubMed · Cited by 774
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Self-citationLocke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
McMenamin, M. E., Soung, P., Perera, S., Kaplan, I. D., Loda, M. F., & Sellers, W. R. (1999) · PubMed · Cited by 727
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., & Wilson, E. M. (2001) · PubMed · Cited by 708
Wang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 687
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659
Transcriptional activation and nuclear targeting signals of the human androgen receptor.
Simental, J. A., Sar, M., Lane, M. V., French, F. S., & Wilson, E. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52466-2 · Cited by 631
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
Bubendorf, L., Kononen, J., Koivisto, P. A., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., & Kallioniemi, O. (1999) · PubMed · Cited by 594
Activation of mitogen-activated protein kinase associated with prostate cancer progression.
Gioeli, D. G., Mandell, J. W., Petroni, G. R., Frierson, H. F., & Weber, M. J. (1999) · PubMed · Cited by 590
Lin, C., Yang, L., Tanasa, B., Hutt, K., Ju, B.-G., Ohgi, K. A., Zhang, J., Rose, D. W., Fu, X.-D., Glass, C. K., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.030 · Cited by 576
Loblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1949 · Cited by 555
Lorenzo, G. D., Tortora, G., D’Armiento, F. P., Rosa, G. D., Staibano, S., Autorino, R., D’Armiento, M., Laurentiis, M. D., Placido, S. D., Catalano, G., et al. (2002) · PubMed · Cited by 553
Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.
Lin, B., Ferguson, C., White, J. T., Wang, S., Vessella, R. L., True, L. D., Hood, L., & Nelson, P. S. (1999) · PubMed · Cited by 531
Jenster, G., van der Korput, H. A. G. M., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., & Brinkmann, A. O. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-10-1396 · Cited by 523
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.371 · Cited by 477
He, B., Kemppainen, J. A., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 442
Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G. C., Klocker, H., & Čulig, Z. (1998) · PubMed · Cited by 437
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2006) · Journal of Urology · doi:10.1016/s0022-5347(06)00096-6 · Cited by 435
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Activation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424
Jenster, G., van der Korput, H. A. G. M., Trapman, J., & Brinkmann, A. O. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7341 · Cited by 419
Zhou, Z. X. (1995) · Molecular Endocrinology · doi:10.1210/me.9.2.208 · Cited by 411
Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., & Murai, M. (2000) · PubMed · Cited by 398
Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer
Mani, R.-S., Tomlins, S. A., Callahan, K., Ghosh, A., Nyati, M. K., Varambally, S., Palanisamy, N., & Chinnaiyan, A. M. (2009) · Science · doi:10.1126/science.1178124 · Cited by 391
Androgen receptors in endocrine‐therapy‐resistant human prostate cancer
van der Kwast, T. H., Schalken, J., de Winter, J. A. R., van Vroonhoven, J. C. C., Mulder, E., Boersma, W., & Trapman, J. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480206 · Cited by 386
ADLER, H. L., McCURDY, M. A., KATTAN, M. W., TIMME, T. L., SCARDINO, P. T., & THOMPSON, T. C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)62092-5 · Cited by 386
Ueda, T., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108255200 · Cited by 381
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0125 · Cited by 366
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.102 · Cited by 364
Molecular regulation of androgen action in prostate cancer.
Dehm, S. M., & Tindall, D. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20794 · Cited by 336
Self-citation(1994) · PubMed Central · Cited by 328
Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S., & Ghosh, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0272 · Cited by 324
Mehra, R., Tomlins, S. A., Shen, R., Nadeem, O., Wang, L., Wei, J. T., Pienta, K. J., Ghosh, D., Rubin, M. A., Chinnaiyan, A. M., et al. (2007) · Modern Pathology · doi:10.1038/modpathol.3800769 · Cited by 303
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286
Interleukin-6: A candidate mediator of human prostate cancer morbidity
Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W.-S., Kim, W. Y., & Simons, J. W. (1995) · Urology · doi:10.1016/s0090-4295(99)80034-x · Cited by 286
Interleukin-8 Is a Molecular Determinant of Androgen Independence and Progression in Prostate Cancer
Araki, S., Omori, Y., Lyn, D., Singh, R. K., Meinbach, D. M., Sandman, Y., Lokeshwar, V. B., & Lokeshwar, B. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1162 · Cited by 275
Rapid signalling by androgen receptor in prostate cancer cells
Peterziel, H., Mink, S., Schonert, A., Becker, M., Klocker, H., & Cato, A. C. (1999) · Oncogene · doi:10.1038/sj.onc.1203032 · Cited by 271
Sadar, M. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7777 · Cited by 270
Interleukin-6 regulation of prostate cancer cell growth.
Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20477 · Cited by 269
Alen, P., Claessens, F., Verhoeven, G., Rombauts, W., & Peeters, B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6085 · Cited by 268
Afar, D., Vivanco, I., Hubert, R., Kuo, J., Chen, E., Saffran, D. C., Raitano, A. B., & Jakobovits, A. (2001) · PubMed · Cited by 266
Sadi, M. V., Walsh, P. C., & Barrack, E. R. (1991) · Cancer · doi:10.1002/1097-0142(19910615)67:12<3057::aid-cncr2820671221>3.0.co;2-s · Cited by 263
Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M. (2001) · Urology · doi:10.1016/s0090-4295(01)01405-4 · Cited by 261
Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins
Ma, H., Hong, H., Huang, S.-M., Irvine, R. A., Webb, P., Kushner, P. J., Coetzee, G. A., & Stallcup, M. R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6164 · Cited by 256
SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival
Zhou, H.-J., Yan, J., Luo, W., Ayala, G., Lin, S.-H., Erdem, H., Ittmann, M., Tsai, S. Y., & Tsai, M.-J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4076 · Cited by 246
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M., & Tilley, W. D. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00525 · Cited by 240
Latil, A., Bièche, I., Vidaud, D., Lidereau, R., Berthon, P., Cussenot, O., & Vidaud, M. (2001) · PubMed · Cited by 239
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
Claessens, F., Denayer, S., Van Tilborgh, N., Kerkhofs, S., Helsen, C., & Haelens, A. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06008 · Cited by 231
Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan, G., Greenberg, N. M., Scher, H. I., Harris, J. M., Marshall, V. R., & Tilley, W. D. (2001) · PubMed · Cited by 227
Harman, S. M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.11.4258 · Cited by 226
Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer.
Inoue, K., Slaton, J. W., Kim, S. J., Perrotte, P., Eve, B. Y., Bar‐Eli, M., Radinsky, R., & Dinney, C. P. (2000) · PubMed · Cited by 222
Hsiao, P.-W., Lin, D.-L., Nakao, R., & Chang, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20229 · Cited by 221
p300 in prostate cancer proliferation and progression.
Debes, J. D., Sebo, T. J., Lohse, C. M., Murphy, L. M., Haugen, D. A. L., & Tindall, D. J. (2003) · PubMed · Cited by 219
Self-citationAbreu-Martin, M. T., Chari, A., Palladino, A. A., Craft, N. A., & Sawyers, C. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.5143 · Cited by 216
Dorff, T. B., Goldman, B., Pinski, J. K., Mack, P. C., Lara, P. N., Van Veldhuizen, P. J., Quinn, D. I., Vogelzang, N. J., Thompson, I. M., & Hussain, M. H. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3122 · Cited by 212
Steinkamp, M. P., O'Mahony, O. A., Brogley, M., Rehman, H., LaPensee, E. W., Dhanasekaran, S., Hofer, M. D., Kuefer, R., Chinnaiyan, A., Rubin, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3605 · Cited by 210
Canil, C. M., Moore, M. J., Winquist, E., Baetz, T., Pollak, M., Chi, K. N., Berry, S., Ernst, D. S., Douglas, L., Brundage, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.129 · Cited by 210
Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., & Sutherland, R. L. (2001) · PubMed · Cited by 208
Ayala, G., Thompson, T., Yang, G., Frolov, A., Li, R., Scardino, P., Ohori, M., Wheeler, T., & Harper, W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0477 · Cited by 207
Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions
Loy, C. J., Sim, K. S., & Yong, E. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0736237100 · Cited by 201
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer
Gnanapragasam, V. J., Leung, H. Y., Pulimood, A. S., Neal, D. E., & Robson, C. N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2179 · Cited by 189
The FXXLF Motif Mediates Androgen Receptor-specific Interactions with Coregulators
He, B., Minges, J. T., Lee, L. W., & Wilson, E. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111975200 · Cited by 189
Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
Wu, J. D., Haugk, K., Woodke, L., Nelson, P., Coleman, I., & Plymate, S. R. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20929 · Cited by 188
HALVORSEN, O. J., Haukaas, S. A., & Akslen, L. A. (2003) · PubMed · Cited by 186
Chen, C. D., & Sawyers, C. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2862-2870.2002 · Cited by 184
Jin, R. J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., Case, T. C., Ellwood-Yen, K., Sawyers, C. L., Bhowmick, N. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0107 · Cited by 182
Targeting Aurora Kinases for the Treatment of Prostate Cancer
Lee, E. C. Y., Frolov, A., Li, R., Ayala, G., & Greenberg, N. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2796 · Cited by 182
Rajput, A. B., Miller, M. A., De Luca, A., Boyd, N., Leung, S., Hurtado-Coll, A., Fazli, L., Jones, E. C., Palmer, J. B., Gleave, M. E., et al. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043810 · Cited by 175
Smith, D. F., & Toft, D. O. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0089 · Cited by 173
Compartmentalization of androgen receptor protein–protein interactions in living cells
van Royen, M. E., Cunha, S. M., Brink, M. C., Mattern, K. A., Nigg, A. L., Dubbink, H. J., Verschure, P. J., Trapman, J., & Houtsmuller, A. B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200609178 · Cited by 170
Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer
Veltri, R. W., Miller, M. C., Zhao, G., Ng, A., Marley, G. M., Wright, G. L., Vessella, R. L., & Ralph, D. (1999) · Urology · doi:10.1016/s0090-4295(98)00455-5 · Cited by 169
Contribution of the Androgen Receptor to Prostate Cancer Predisposition and Progression
Buchanan, G., Irvine, R. A., Coetzee, G. A., & Tilley, W. D. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1015531326689 · Cited by 165
Androgen Receptor Nuclear Translocation Is Facilitated by the f-Actin Cross-Linking Protein Filamin
Ozanne, D. M., Brady, M. E., Cook, S., Gaughan, L., Neal, D. E., & Robson, C. N. (2000) · Molecular Endocrinology · doi:10.1210/me.14.10.1618 · Cited by 162
Malinowska, K., Neuwirt, H., Cavarretta, I. T., Bektic, J., Steiner, H., Dietrich, H., Moser, P. L., Fuchs, D., Hobisch, A., & Culig, Z. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0174 · Cited by 157
Chodak, G. W., Kranc, D. M., Puy, L. A., Takeda, H., Johnson, K., & Chang, C. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37389-5 · Cited by 156
Traish, A. M., & Morgentaler, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605376 · Cited by 148
Wallner, L., Dai, J., Escara-Wilke, J., Zhang, J., Yao, Z., Lu, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3447 · Cited by 144
Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., O'Sullivan, J. M., Johnston, P. G., & Waugh, D. J. J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn109 · Cited by 143
Lessard, L., Bégin, L. R., Gleave, M. E., Mes-Masson, A.-M., & Saad, F. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602796 · Cited by 140
Molecular Determinants of Resistance to Antiandrogen Therapy
Ratliff, T. L. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000141478.13478.c3 · Cited by 140
Expression of Androgen Receptor Coregulators in Prostate Cancer
Linja, M. J., Porkka, K. P., Kang, Z., Savinainen, K. J., Jänne, O. A., Tammela, T. L. J., Vessella, R. L., Palvimo, J. J., & Visakorpi, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0990-3 · Cited by 139
Heterogeneous Expression and Functions of Androgen Receptor Co-Factors in Primary Prostate Cancer
Li, P., Yu, X., Ge, K., Melamed, J., Roeder, R. G., & Wang, Z. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64422-7 · Cited by 137
Wright, A. S., Thomas, L. N., Douglas, R. C., Lazier, C. B., & Rittmaster, R. S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119074 · Cited by 134
Tilley, W. D., Lim-Tio, S. S., Horsfall, D. J., Aspinall, J. O., Marshall, V. R., & Skinner, J. M. (1994) · PubMed · Cited by 131
Kraus, S., Gioeli, D., Vomastek, T., Gordon, V., & Weber, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0596 · Cited by 118
Takayama, K., Kaneshiro, K., Tsutsumi, S., Horie‐Inoue, K., Ikeda, K., Urano, T., Ijichi, N., Ouchi, Y., Shirahige, K., Aburatani, H., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210229 · Cited by 118
Smith, P. C., & Keller, E. T. (2001) · The Prostate · doi:10.1002/pros.1080 · Cited by 116
Ricciardelli, C., Choong, C. S., Buchanan, G., Vivekanandan, S., Neufing, P. J., Stahl, J., Marshall, V. R., Horsfall, D. J., & Tilley, W. D. (2004) · The Prostate · doi:10.1002/pros.20154 · Cited by 116
Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells.
Nadiminty, N., Lou, W., Sun, M., Chen, J., Yue, J., Kung, H.-J., Evans, C. P., Zhou, Q., & Gao, A. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3703 · Cited by 113
Chamberlain, N. L., Whitacre, D. C., & Miesfeld, R. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.26772 · Cited by 113
Interplay between two hormone-independent activation domains in the androgen receptor.
Callewaert, L., Van Tilborgh, N., & Claessens, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2389 · Cited by 111
Xu, L. L., Su, Y. P., Labiche, R., Segawa, T., Shanmugam, N., McLeod, D. G., Moul, J. W., & Srivastava, S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1196 · Cited by 108
Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells
Heemers, H. V., Sebo, T. J., Debes, J. D., Regan, K. M., Raclaw, K. A., Murphy, L. M., Hobisch, A., Culig, Z., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2836 · Cited by 107
Self-citationLiu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H. S., & Whang, Y. E. (2010) · Oncogene · doi:10.1038/onc.2010.103 · Cited by 106
Singh, R. K., & Lokeshwar, B. L. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-57 · Cited by 105
Androgen-Induced TMPRSS2:ERG Fusion in Nonmalignant Prostate Epithelial Cells
Bastus, N. C., Boyd, L. K., Mao, X., Stankiewicz, E., Kudahetti, S. C., Oliver, R. T. D., Berney, D. M., & Lu, Y. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1638 · Cited by 105
Cytokine disbalance in common human cancers
Čulig, Z. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.12.010 · Cited by 103
Androgen-Induced Cell Migration: Role of Androgen Receptor/Filamin A Association
Castoria, G., D'Amato, L., Ciociola, A., Giovannelli, P., Giraldi, T., Sepe, L., Paolella, G., Barone, M. V., Migliaccio, A., & Auricchio, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017218 · Cited by 102
Asim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., & Mukhtar, H. (2008) · Oncogene · doi:10.1038/sj.onc.1211016 · Cited by 101
Hu, Y.-C., Yeh, S., Yeh, S.-D., Sampson, E. R., Huang, J., Li, P., Hsu, C.-L., Ting, H.-J., Lin, H.-K., Wang, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401781200 · Cited by 98
Expression of NF‐κB in prostate cancer lymph node metastases
A, H. I., Lessard, L., Mes‐Masson, A., & Fred Saad, C. (2003) · The Prostate · doi:10.1002/pros.10335 · Cited by 97
Dehm, S. M. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.09.006 · Cited by 96
Debes, J. D., Comuzzi, B., Schmidt, L. J., Dehm, S. M., Culig, Z., & Tindall, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2837 · Cited by 92
Chen, C., Lewis, S. K., Voigt, L. F., Fitzpatrick, A. L., Plymate, S. R., & Weiss, N. S. (2004) · Cancer · doi:10.1002/cncr.20727 · Cited by 91
Whang, Y. E., Armstrong, A. J., Rathmell, W. K., Godley, P. A., Kim, W. Y., Pruthi, R. S., Wallen, E., Crane, J. M., Moore, D. T., Grigson, G., et al. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.09.018 · Cited by 89
Aurora‐A over‐expression in high‐grade PIN lesions and prostate cancer
Buschhorn, H. M., Klein, R. R., Chambers, S. M., Hardy, M. C., Green, S., Bearss, D. J., & Nagle, R. B. (2005) · The Prostate · doi:10.1002/pros.20247 · Cited by 86
Dehm, S. M., Regan, K. M., Schmidt, L. J., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1267 · Cited by 84
Self-citationWang, Y., Kreisberg, J. I., Bedolla, R. G., Михайлова, М. А., White, R. D., & Ghosh, P. (2007) · Oncogene · doi:10.1038/sj.onc.1210435 · Cited by 81
Jia, L., Choong, C. S.-Y., Ricciardelli, C., Kim, J., Tilley, W. D., & Coetzee, G. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3486 · Cited by 80
Evaluation of Ligand-Dependent Changes in AR Structure Using Peptide Probes
Chang, C.-Y. (2002) · Molecular Endocrinology · doi:10.1210/me.16.4.647 · Cited by 80
Loss of PTEN is associated with progression to androgen independence
Bertram, J., Peacock, J. W., Fazli, L., Mui, A. L.-F., Chung, S. W., Cox, M. E., Monia, B., Gleave, M. E., & Ong, C. J. (2006) · The Prostate · doi:10.1002/pros.20411 · Cited by 78
Lyons, L. S., & Burnstein, K. L. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0346 · Cited by 76
Pleiotropic functional properties of androgen receptor mutants in prostate cancer
Bergerat, J.-P., & Céraline, J. (2009) · Human Mutation · doi:10.1002/humu.20848 · Cited by 75
Ryan, C. J., Smith, A., Lal, P., Satagopan, J. M., Reuter, V. E., Scardino, P. T., Gerald, W. L., & Scher, H. I. (2006) · Urology · doi:10.1016/j.urology.2006.04.016 · Cited by 72
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Oudes, A. J., Roach, J. C., Walashek, L. S., Eichner, L. J., True, L. D., Vessella, R. L., & Liu, A. Y. C. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-86 · Cited by 70
Coactivator selective regulation of androgen receptor activity
Agoulnik, I. U., & Weigel, N. L. (2009) · Steroids · doi:10.1016/j.steroids.2009.02.007 · Cited by 69
Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons, L. S., Rao, S., Balkan, W., Faysal, J., Maiorino, C. A., & Burnstein, K. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0158 · Cited by 67
Mestayer, C., Blanchere, M., Jaubert, F., Dufour, B., & Mowszowicz, I. (2003) · The Prostate · doi:10.1002/pros.10229 · Cited by 66
Klein, E. A., Ciezki, J. P., Kupelian, P. A., & Mahadevan, A. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.04.001 · Cited by 63
Kaku, N., Matsuda, K.-I., Tsujimura, A., & Kawata, M. (2008) · Endocrinology · doi:10.1210/en.2008-0137 · Cited by 58
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer
Schmidt, L. J., & Tindall, D. J. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.09.003 · Cited by 58
Self-citationLéotoing, L., Manin, M., Monté, D., Baron, S., Communal, Y., Lours-Calet, C., VEYSSIERE, G., Morel, L., & Beaudoin, C. (2007) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0021 · Cited by 57
An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells.
Aaronson, D. S., Muller, M., Neves, S. R., Chung, W.-C., Jayaram, G., Iyengar, R., & Ram, P. T. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.02.006 · Cited by 47
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Kibel, A. S. (2011) · Yearbook of Urology · doi:10.1016/j.yuro.2011.05.029 · Cited by 47
Agoulnik, I. U., Bingman, W. E., Nakka, M., Li, W., Wang, Q., Liu, X. S., Brown, M., & Nancy L., N. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0481 · Cited by 36
Regulation of Androgen Receptor Activity by Tyrosine Phosphorylation
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.010 · Cited by 21
Duff, J., Davies, P., Watt, K., & McEwan, I. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341098 · Cited by 16
Bosland, M. C. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.07.013 · Cited by 13
Gordon, M. S. (2007) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)70516-5 · Cited by 11
Cited by
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4283 · Cited by 1,004
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Reiter, R., Rosales-Corral, S., Tan, D.-X., Acuna-Castroviejo, D., Qin, L., Yang, S.-F., & Xu, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040843 · Cited by 433
Obesity and Cancer Mechanisms: Cancer Metabolism
Hopkins, B. D., Goncalves, M. D., & Cantley, L. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9712 · Cited by 414
Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers
Honda, S., Loher, P., Shigematsu, M., Palazzo, J. P., Suzuki, R., Imoto, I., Rigoutsos, I., & Kirino, Y. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510077112 · Cited by 386
Metadata
- Authors
- Tindall, D., & Lonergan, P.
- Venue
- Journal of Carcinogenesis
- Publisher
- Sakun Publishing House
- Published
- 2011
- Volume
- 10
- Issue
- 1
- Pages
- 20
- ISSN
- 0974-6773 (ISSN-L)
- 1477-3163
- OpenAlex
- W1996956937
- Cited by
- 535
- References
- 157
- FWCI
- 16.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.